Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
UBS
Julphar
Daiichi Sankyo
Argus Health
AstraZeneca
Cantor Fitzgerald
Johnson and Johnson
Citi

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,676,967

« Back to Dashboard

Summary for Patent: 6,676,967
Title: Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
Abstract:Methods for reducing flushing in individuals being treated for hyperlipidemia with nicotinic acid are disclosed. According to the methods of the present invention, flushing can be reduced in individuals under going nicotinic acid therapy without causing drug-induced hepatotoxicity to a level that would require the nicotinic acid therapy to be discontinued by orally administering to the individuals intermediate nicotinic acid formualtions having unique biopharmaceutical characteristics as a single dose once per day. While the methods of the present invention contemplate administering the intermediate release nicotinic acid formulations at any time during a 24 hour period, it is preferable to administer them once-a-day as a single dose during the evening or at night between about 6:00 pm. and 12:00 a.m., preferably between about 8:00 p.m. and 12:00 a.m., and most preferably between about 8:00 p.m. and 10:00 p.m.
Inventor(s): Cefali; Eugenio A. (Fort Lauderdale, FL), Bova; David J. (Boca Raton, FL)
Assignee: KOS Pharmaceuticals, Inc. (Miami, FL)
Application Number:08/962,422
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,676,967
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Device;

Drugs Protected by US Patent 6,676,967

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Cipla
McKinsey
QuintilesIMS
Baxter
Queensland Health
Johnson and Johnson
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.